Skip to main content
Signal8

NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets

$ELABPress releaseJun 18, 2026, 7:30 AM ETRead the release

NorthStrive Biosciences, a subsidiary of PMGC Holdings (ELAB), filed two new U.S. patent applications covering the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight loss. The filings expand the company's intellectual property portfolio from animal health into potential human-use applications, targeting muscle loss from sarcopenia, malnutrition, and physical inactivity.

Key figures

Patent applications
["19/709,895","19/709,950"]

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ELAB: NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets — AI Analysis | Signal8